Suit against Arden
This article was originally published in The Rose Sheet
Executive Summary
The Stephan Company has filed a lawsuit against Elizabeth Arden for infringing its federally registered Interlude trademark for personal care products and fragrances, company announces June 22. Filed in the U.S. District Court for the Southern District of New York, suit seeks an injunction barring Elizabeth Arden from selling Provocative Interlude fragrance and products, which are on sale in fine department stores. Arden launched Provocative Interlude in April (1"The Rose Sheet" April 3, 2006, Marketing In Brief). Stephan notes blocking further sales of the Provocative scent will prevent consumer confusion...
You may also be interested in...
Arden responds to suit
Lawsuit filed by The Stephan Company against Elizabeth Arden for infringing its federally registered Interlude trademark is "entirely without merit," Elizabeth Arden states in June 22 press release responding to allegations. "In fact, the U.S. Trademark Office granted Elizabeth Arden a registration for the Provocative Interlude name and will fully assert its legal rights in this matter," Arden adds. Filed in the U.S. District Court for the Southern District of New York, Stephan's suit seeks an injunction barring Elizabeth Arden from selling Provocative Interlude fragrance and products (1"The Rose Sheet" June 26, 2006, In Brief)...
Marketing In Brief
Elizabeth Arden: Provocative Woman Interlude fragrance will debut in April, company says. Scent opens with notes of sparkling champagne, wild berries and guava leaf, which warm to a heart of sunset orchid, rose petals and mango flower. Drydown comprises cashmere musk, white chocolate and redwood. Interlude is positioned as a "fragrance that creates an intimate yet alluring and daring aura of seduction," Arden says. Scent will retail in 1.7 oz. and 3.4 oz. edp sprays for $42.50 and $52.50, respectively. Elizabeth Arden Provocative Women debuted in 2004 (1"The Rose Sheet" Feb. 16, 2004, Marketing in Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.